Bosch Packaging Technology Aims to Keep Strengthening its Leading Position Until 2020
By 2020, Bosch Packaging Technology aims to grow considerably faster than the market, and to further expand its leading position in the realm of process and packaging technology around the world.
“We expect to see fundamental change in the market for packaging machinery. We not only want to react to this change, we also aim to help shape it,” said Friedbert Klefenz, President of Bosch Packaging Technology, during the company's press conference at the Interpack trade show in Düsseldorf. On the basis of its PA 2020 strategy, the manufacturer of special machinery aims to continue expanding its business in the established markets, and to grow especially in Asia and Africa. In addition, the company intends to spur further growth by venturing into new fields of business.
“We are well on our way to realizing our plans,” Klefenz said. Last year, Bosch Packaging Technology's sales exceeded the one-billion euro mark for the first time. In fiscal 2013, the company increased its sales by 22%, from 914 million euro to 1.1 billion euro. This was largely the result of the first-time consolidation of companies such as Hüttlin, Manesty and Eisai Machinery. After adjusting for consolidation effects, growth was 6.4%. Currency effects notwithstanding, Packaging Technology recorded internal growth of 10%. According to VDMA, a trade association, the packaging machinery sector grew 4% in 2013. Including companies that were consolidated for the first time in the year under review, the company employed 5600 associates at more than 30 locations, 12% more than the previous year.
Moving Toward the Next Decade with the PA 2020 Strategy
“We expect to keep up this pace of growth in the coming years as well. By the end of 2015, our annual sales are likely to reach the 1.5 billion euro mark,” said Klefenz. “But our plans also go beyond 2015.” Last year, the company defined its strategy up to the end of this decade with PA 2020. The strategy's central aim is to expand the company's current fields of business and markets and to venture into new ones.
Regional Shift Expected
At present, Bosch Packaging Technology generates around 40% of its sales in Europe, 30% in Asia, and a quarter in North and South America. However, for the coming years, a strong regional shift is expected. “Until the end of this decade, we aim to continue growing strongly in the established markets, such as Europe and North America. At the same time, we will generate far more than a third of our sales in Asia,” said Klefenz. Africa and the Middle East are also gaining significance. “Markets in Europe and the Americas will keep developing continuously. This means that the overall market for packaging machinery will grow. However, in the coming years, there will be a shift in the importance of regional markets,” said Klefenz.
Pharma Segment Growing Strongly
The pharma segment is one of the drivers of Bosch Packaging Technology's growth. The company has benefited from the sector's dynamic global development. In the past year, it grew 9%. In total, this field of business accounts for 52% of the company's sales. “This shows that a growing number of people have access to medication. It is also the result of the global growth of the generics business,” said Klefenz. At the same time, more complex substances and the ever-stricter requirements of manufacturers and lawmakers have placed growing demands on the packaging industry. “This calls for major innovative strength,” said Klefenz. In total, Bosch Packaging Technology spent around 4.5% of its sales on research and development in 2013.
To read more, click here.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.